Abstract
Metastasis remains the major driver of mortality in patients with cancer. Our growing body of knowledge regarding this process provides the basis for the development of molecularly targeted therapeutics aimed at the tumor cell or its interaction with the host microenvironment. Here we discuss the similarity and differences between primary tumors and metastases, pathways controlling the colonization of a distant organ, and incorporation of antimetastatic therapies into clinical testing.
Key Points
-
Most information on human cancer is obtained from analysis of primary tumors and yet this knowledge is applied to the treatment of metastases
-
There is mounting genetic evidence that the molecular wiring of a metastatic lesion has both elements in common with and elements that are distinct from those of primary tumors
-
Targeting the last step in the metastatic process, outgrowth at a distant site, termed 'metastatic colonization', holds great therapeutic promise
-
Blockade of metastatic colonization can be accomplished by targeting the metastatic cancer cell or the host cell, or by interrupting reciprocal interactions between tumor cells and the foreign microenvironment; therapeutic efforts can target metastatic colonization at all sites or interactions specific to a particular organ (bone, for instance)
-
Novel clinical trial designs with short-term molecular and pharmacodynamic end points should be considered
-
Approaches to inhibit metastatic colonization may show their best efficacy in the adjuvant setting
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895–904
Gupta GP and Massague J (2006) Cancer metastasis: building a framework. Cell 127: 679–695
Hoang CD et al. (2005) Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs. Cancer Detect Prev 29: 509–517
Roepman P et al. (2006) Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis. Cancer Res 66: 11110–11114
Wang L et al. (2006) Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray. World J Gastroenterol 12: 6949–6954
Yanagawa R et al. (2001) Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 3: 395–401
Hao X et al. (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100: 1110–1122
Inokuchi M et al. (2004) Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol 53: 391–396
Feldmann G et al. (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67: 2187–2196
Suzuki M and Tarin D (2007) Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol 1: 172–180
Diep CB et al. (2006) The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 45: 31–41
Albanese I et al. (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325: 784–791
Shah RB et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209–9216
Rinker-Schaeffer CW et al. (2006) Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 12: 3882–3889
Nash KT et al. (2007) Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99: 309–321
Chekmareva M et al. (1998) Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res 58: 4963–4969
Nagle JA et al. (2004) Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 24: 9726–9735
Martin SS et al. (2004) A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23: 4641–4645
Criscuoli ML et al. (2005) Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 105: 1508–1514
Witz IP and Levy-Nissenbaum O (2006) The tumor microenvironment in the post-PAGET era. Cancer Lett 242: 1–10
Postovit LM et al. (2006) Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 66: 7833–7836
Al-Mehdi A et al. (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6: 100–102
Kaplan RN et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820–827
VanderGriend D et al. (2005) Suppression of metastatic colonization by the context-dependent activation of the c-jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 65: 10984–10991
Hicklin DJ and Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011–1027
Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
Van den Eynden GG et al. (2007) Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clin Exp Metastasis 24: 13–23
Casanovas O et al. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299–309
Dorrell MI et al. (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104: 967–972
Wang J et al. (2007) A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res 67: 149–159
Stessels F et al. (2004) Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 90: 1429–1436
Kusters B et al. (2002) Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 62: 341–345
Noguera-Troise I et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032–1037
Ridgway J et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083–1087
MacKie RM et al. (2003) Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 348: 567–568
Naumov G et al. (2002) Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 62: 2162–2168
Holmgren L et al. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149–153
Nierodzik ML and Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10: 355–362
Dalton W (1999) The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat 2: 285–288
Neville-Webbe HL et al. (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86: 269–279
Efstathiou E et al. (2007) Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13: 1224–1231
Bird NC et al. (2006) Biology of colorectal liver metastases: a review. J Surg Oncol 94: 68–80
Deeken JF and Loscher W (2007) The blood–brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 13: 1663–1674
Palmieri D et al. (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13: 1656–1662
Roodman G (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655–1664
Kang Y et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537–549
Roudier MP et al. (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34: 646–653
Mundy G (2002) Metastasis to the bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593
Kishida Y et al. (2007) Parthenolide, a natural inhibitor of nuclear factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 13: 59–67
Shannon KE et al. (2004) Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis 21: 129–138
Khalili P et al. (2005) Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene 24: 6657–6666
Slamon D et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792
Piccart-Gebhart MJ et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672
Romond EH et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684
Tosi P et al. (2006) First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 76: 399–404
Body J et al. (2002) A phase I study of AMGN-007, a recombinant osterogrotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (3 Suppl): 887–892
Body JJ et al. (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221–1228
Bochner BH et al. (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24: 3967–3972
Wedam S et al. (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24: 769–777
Jubb AM et al. (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217–227
Lise M et al. (2005) Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Front Biosci 10: 3042–3057
Herbst RS et al. (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 2544–2555
Hainsworth JD et al. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889–7896
Miller KD et al. (2005) A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11: 3369–3376
Paterson AH (2006) The role of bisphosphonates in early breast cancer. Oncologist 11 (Suppl 1): S13–S19
Diel I et al. (1994) Monoclonal antibodies to detect breast cancer cells in bone marrow. In Important Advances in Oncology, 143–164 (Eds De Vita VT et al.) Philadelphia: Lippincott
Saarto T et al. (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients; 5-year results of a randomized controlled trial. J Clin Oncol 19: 10–17
Powles T et al. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219–3224
Saarto T et al. (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43: 650–656
Bertelli G et al. (2006) Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 57: 46–51
Nelson JB et al. (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 1063–1069
Carducci MA and Jimeno A (2006) Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12: S6296–S6300
Nelson JB et al. (2003) Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169: 1143–1149
Body JJ et al. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97: 887–892
Body JJ et al. (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221–1228
Palmieri D et al. (2005) Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 97: 632–642
Titus B et al. (2005) Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65: 7320–7327
Horak C et al. (2007) Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res 67: 11751–11759
Orsini MJ et al. (2007) Metastin (KiSS-1) mimetics identified from peptide structure-activity relationship-derived pharmacophores and directed small molecule database screening. J Med Chem 50: 462–471
Gupta GP et al. (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765–770
Kang Y et al. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102: 13909–13914
Nam JS et al. (2006) Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66: 6327–6335
Zhang Q et al. (2006) Blockade of transforming growth factor-β signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther 5: 1733–1743
Biswas S et al. (2007) Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117: 1305–1313
Biswas S et al. (2006) Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 12: 4142–4146
Ono K et al. (2006) Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC. Bone 39: 27–34
Peruzzi B and Bottaro DP (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657–3660
Rucci N et al. (2006) Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 318: 161–172
Jallal H et al. (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67: 1580–1588
Al-Hajj M et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983–3988
Jones DH et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692–696
Park BK et al. (2007) NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13: 62–69
Horsman MR and Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520–11539
Bandyopadhyay A et al. (2006) Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66: 6714–6721
Lang JY et al. (2005) Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res 11: 3455–3464
Palm D et al. (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118: 2744–2749
Giubellino A et al. (2007) Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 67: 6012–6016
Cairns RA and Hill RP (2004) Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 64: 2054–2061
Cassinelli G et al. (2006) Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 5: 2388–2397
Acknowledgements
PS Steeg was funded by the Intramural research program of the Center for Cancer Research, NCI, and D Theodorescu was supported by NIH grants CA104106 and CA075115.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Selected reports comparing primary tumors and metastases (DOC 101 kb)
Supplementary Table 2
Selected preclinical studies for bone metastasis (DOC 66 kb)
Supplementary Table 3
Selected anti-angiogenesis clinical trials in the metastatic setting (DOC 54 kb)
Rights and permissions
About this article
Cite this article
Steeg, P., Theodorescu, D. Metastasis: a therapeutic target for cancer. Nat Rev Clin Oncol 5, 206–219 (2008). https://doi.org/10.1038/ncponc1066
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1066
This article is cited by
-
The role of Aquaporins in tumorigenesis: implications for therapeutic development
Cell Communication and Signaling (2024)
-
rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
Journal of Experimental & Clinical Cancer Research (2023)
-
The activated CD36-Src axis promotes lung adenocarcinoma cell proliferation and actin remodeling-involved metastasis in high-fat environment
Cell Death & Disease (2023)
-
Major regulators of the multi-step metastatic process are potential therapeutic targets for breast cancer management
Functional & Integrative Genomics (2023)
-
Mechanisms of breast cancer metastasis
Clinical & Experimental Metastasis (2022)